CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

Bookmark and Share
Published: 29 Sep 2019
Views: 474
Rating:
Save
Prof George Sledge - Stanford Health Care, Stanford, USA

Prof George Sledge presents data data from the MONARCH 2 trial during a press conference at the 2019 ESMO congress.

The MONARCH 2 trial looked at the CDK4/6 inhibitor abemaciclib plus fulvestrant in pre-, and peri- and postmenopausal breast cancer patients.

Watch Prof Sledge's interview with ecancer here.

Read more about the study here.